Scale ready JPT Peptide Technologies operates a large peptide synthesis capacity (over 1 million peptides per year) with capabilities ranging from micro to large-scale synthesis, signaling a strong fit for customers needing high-volume production or rapid scale-up.

Modified peptide solutions The portfolio includes extensive modified peptides (macrocyclic, PTMs, labeled, biotinylated, dyes, conjugations, isotope labeling) and BioTides, indicating opportunities to upsell advanced customization for therapeutic, diagnostic, and research applications.

Clinical and immune focus Clinical grade peptides and PepMix pools support immunotherapy, vaccine development, immune monitoring, and cell therapy development, positioning JPT to target pharma, biotech, and clinical researchers pursuing immune-focused programs.

Global and compliant Manufacturing in Germany with international support and adherence to ethical, environmental, and health standards suggests reliability for global collaborations and projects requiring stringent quality and regulatory alignment.

Strategic growth signals Recent announcements of new tools (BioTides), an ultra high throughput SPOT platform, and expanded Berlin facilities, coupled with ongoing business development hires, indicate capacity to support rapid expansion, personalized therapies, and cross-border engagements.